In Vivo Validation of Novel P53-Independent Therapeutic Modalities for Small Cell Lung Cancer (SCLC).
Kai Kang,Nathan Radakovich,Arjun Khunger,David S. Schrump,David MacPherson,Mark P. Rubinstein,John M. Wrangle,Yogen Saunthararajah,Vamsidhar Velcheti
DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e24141
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:e24141 Background: Current treatments for SCLC produce transient responses – 2-year survival is 5%. One reason is that the treatments apply stress upstream of p53 to upregulate it (cytotoxicity), but p53 is genetically inactivated in SCLC, enabling ready selection for resistant cells. We are hence developing towards clinical trials new modalities to cytoreduce SCLC by non-cytotoxic, p53-independent mechanisms. Methods: A murine p53-null SCLC cell line (F1339), developed by tracheal infection of Rblox/p53lox mice with Adeno-CMV-Cre, was inoculated into B6/129 mice by tail vein. After documenting engraftment, mice were treated with PBS, etoposide 8 mg/kg 3X/wk + cisplatin 12 mg/kg 1X/wk, THU-Dec/5Aza (10/0.1/1 mg/kg 3X/wk) or anti-PD1 (5 mg/kg q5d) (n = 5/group). Tumor burden, overall survival (OS), drug pharmacodynamics and metabolism, myeloid derived suppressor cells (MDSCs), and T-cells were measured. Results: The SCLC cells were resistant to clinical concentrations of etoposide/cisplatin (ECis), but were sensitive to DNA methyltransferase 1 (DNMT1)-depletion by non-cytotoxic concentrations of the DNMT1-depleting pyrimidine analogue clinical drugs decitabine (Dec 0.5 µM) or 5-azacytidine (5Aza 5 µM). However, the pyrimidine metabolism network in the cells reacted to Dec and 5Aza challenge with shifts in DCK, UCK2 and CDA expression that reflexively dampened drug uptake, causing resistance after 4 weeks in vitro. To outmaneuver these metabolic reflexes, Dec and 5Aza were alternated, and tetrahydrouridine (THU) to inhibit CDA was added. In vivo, THU-Dec/5Aza significantly extended OS ~2-fold (Log rank p < 0.01); decreased tumor burden (PBS 3.53 g, ECis 3.45 g, THU-Dec/5Aza 1.09 g); increased lymphocyte counts (CD4: PBS 0.99, THU-Dec/5Aza 1.81 k/µL, p < 0.01; CD8: PBS 0.8, THU-Dec/5Aza 1.66 k/µL, p < 0.01); and decreased MDSCs (G-MDSC: PBS 0.13, THU-Dec/5Aza 0.03 k/µL, p < 0.01; M-MDSC: PBS 0.28, THU-Dec/5Aza 0.08 k/µL, p < 0.01). Anti-PD1 alone, like ECis, provided minimal benefit in the syngeneic model of SCLC. Conclusions: Pyrimidine metabolism reflexes to Dec/5Aza challenge can be rationally outmaneuvered, for meaningful non-cytotoxic DNMT1-depleting therapy of ECis/anti-PD1-resistant SCLC.